参考文献/References:
[1] MINEO C. Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis[J]. Current Rheumatology Reports, 2013, 15(5): 324.
[2] CORBAN M T, DUARTE-GARCIA A, MCBANE R D, et al. Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics[J]. Journal of the American College of Cardiology, 2017, 69(18): 2317-2330.
[3] SMULSKI C R, EIBEL H. BAFF and BAFF-receptor in B cell selection and survival[J]. Frontiers in Immunology, 2018, 9: 2285.
[4] KYAW T, TOH B H, BOBIK A. Evolving BAFF targeted therapies for preventing acute myocardial infarctions and ischemic strokes[J]. Expert Opinion on Therapeutic Targets, 2020, 24(1): 7-12.
[5] JEREMIC I, DJURIC O, NIKOLIC M, et al. Neutrophil extracellular traps-associated markers are elevated in patients with systemic lupus erythematosus[J]. Rheumatology International, 2019, 39(11): 1849-1857.
[6] WISE L M, STOHL W. The safety of belimumab for the treatment of systemic lupus erythematosus[J]. Expert Opinion on Drug Safety, 2019, 18(12): 1133-1144.
[7] MIYAKIS S, LOCKSHIN M, ATSUMI T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome(APS)[J]. Journal of Thrombosis and Haemostasis, 2006, 4(2): 295-306.
[8] SPINELLI F R, BARBATI C, CECARELLI F, et al. B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus[J]. Arthritis Research & Therapy, 2019, 21(1): 245.
[9] ALVAREZ-RODRIGUEZ L, RIANCHO-ZARRABEITIA L, CALVO-ALéN J, et al. Peripheral B-cell subset distribution in primary antiphospholipid syndrome[J]. International Journal of Molecular Sciences, 2018, 19(2): 589.
[10] WOJDASIEWICZ P, WAJDA A, HA.ADYJ E, et al. IL-35, TNF-α, BAFF, and VEGF serum levels in patients with different rheumatic diseases[J]. Reumatologia, 2019, 57(3): 145-150.
[11] RIHACEK M, BIENERTOVA-VASKU J, VALIK D, et al. B-cell activating factor as a cancer biomarker and its implications in Cancer-related cachexia[J]. BioMed Research International, 2015,2015: 792187.
[12] OIKONOMOU E, LEOPOULOU M, THEOFILIS P, et al. A Link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications[J]. Atherosclerosis, 2020, 309: 16-26.
[13] DONG Xiaoqing, QIN Jiamin, MA Jing, et al. BAFF inhibits autophagy promoting cell proliferation and survival by activating Ca2+-CaMKII-dependent Akt/mTOR signaling pathway in normal and neoplastic B-lymphoid cells [J]. Cellular Signalling, 2019, 53:68-79.
[14] KYAW T, TIPPING P, BOBIK A, et al. Opposing roles of B lymphocyte subsets in atherosclerosis[J]. Autoimmunity, 2017, 50(1): 52-56.
[15] SAIDOUNE F, EVEN G, LAMRI Y, et al. Effects of BAFF neutralization on atherosclerosis associated with systemic lupus erythematosus[J]. Arthritis & Rheumatology,2020, 73(2):255-264.
[16] JACKSON S W, SCHARPING N E, JACOBS H M, et al. Cutting edge: BAFF overexpression reduces atherosclerosis via TACI-Dependent B cell activation[J]. Journal of Immunology (Baltimore, Md. : 1950), 2016, 197(12): 4529-4534.
[17] CHENG Si, HE Chao, ZHOU Hong, et al. The effect of Toll-like receptor 4 on β2-glycoprotein I-induced B cell activation in mouse model[J]. Molecular Immunology, 2016, 71: 78-86.
[18] CHENG Si, WANG Haibo, ZHOU Hong. The role of TLR4 on B cell activation and anti- β2 GPI antibody production in the antiphospholipid syndrome[J]. Journal of Immunology Research,2016, 2016:1719720.
[19] LIU Chuanchuan, WANG Shuching, KAO Chenwei, et al. B cells facilitate platelet production mediated by cytokines in patients with essential thrombocythaemia[J]. Thrombosis and Haemostasis, 2014, 112(3): 537-550.
[20] SAUTER R, SAUTER M, REIS E, et al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis[J]. Circulation, 2018, 138(16): 1720-1735.